These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25296641)

  • 1. The Thoc1 ribonucleoprotein and prostate cancer progression.
    Chinnam M; Wang Y; Zhang X; Gold DL; Khoury T; Nikitin AY; Foster BA; Li Y; Bshara W; Morrison CD; Payne Ondracek RD; Mohler JL; Goodrich DW
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25296641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.
    Möller K; Wecker AL; Höflmayer D; Fraune C; Makrypidi-Fraune G; Hube-Magg C; Kluth M; Steurer S; Clauditz TS; Wilczak W; Simon R; Sauter G; Huland H; Heinzer H; Haese A; Schlomm T; Weidemann S; Luebke AM; Minner S; Bernreuther C; Bonk S; Marx A
    Virchows Arch; 2020 Nov; 477(5):625-636. PubMed ID: 32417965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships of hHpr1/p84/Thoc1 expression to clinicopathologic characteristics and prognosis in non-small cell lung cancer.
    Yang J; Li Y; Khoury T; Alrawi S; Goodrich DW; Tan D
    Ann Clin Lab Sci; 2008; 38(2):105-12. PubMed ID: 18469354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Random forest-based modelling to detect biomarkers for prostate cancer progression.
    Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
    Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis-based study of 428 cases.
    Toubaji A; Sutcliffe S; Chaux A; Lecksell K; Hicks J; De Marzo AM; Platz EA; Netto GJ
    Hum Pathol; 2012 Nov; 43(11):1852-65. PubMed ID: 22554381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Twist-1, E-cadherin and EZH2 in Prostate Cancer: An Immunohistochemical Study.
    Abdelrahman AE; Arafa SA; Ahmed RA
    Turk Patoloji Derg; 2017; 1(1):198-210. PubMed ID: 28832071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of THOC1 and ALY mRNP biogenesis/export factors in human cancers.
    Domínguez-Sánchez MS; Sáez C; Japón MA; Aguilera A; Luna R
    BMC Cancer; 2011 Feb; 11():77. PubMed ID: 21329510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
    Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
    Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Kim YH; Byun YJ; Kim WT; Jeong P; Yan C; Kang HW; Kim YJ; Lee SC; Moon SK; Choi YH; Yun SJ; Kim WJ
    J Korean Med Sci; 2018 Nov; 33(47):e303. PubMed ID: 30450027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer.
    Chen QB; Liang YK; Zhang YQ; Jiang MY; Han ZD; Liang YX; Wan YP; Yin J; He HC; Zhong WD
    Tumour Biol; 2017 Jun; 39(6):1010428317703924. PubMed ID: 28651494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.
    Tsourlakis MC; Schoop M; Plass C; Huland H; Graefen M; Steuber T; Schlomm T; Simon R; Sauter G; Sirma H; Minner S
    Hum Pathol; 2013 Sep; 44(9):1789-96. PubMed ID: 23642739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
    Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
    Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins.
    Kurose H; Ueda K; Kondo R; Ogasawara S; Kusano H; Sanada S; Naito Y; Akiba J; Kakuma T; Igawa T; Yano H
    Anticancer Res; 2019 Feb; 39(2):957-964. PubMed ID: 30711981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asporin is a stromally expressed marker associated with prostate cancer progression.
    Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
    Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers.
    Krajewska M; Turner BC; Shabaik A; Krajewski S; Reed JC
    Prostate; 2006 Jun; 66(8):801-10. PubMed ID: 16482527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.
    Marx A; Luebke AM; Clauditz TS; Steurer S; Fraune C; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Möller-Koop C; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Meiners J
    Dis Markers; 2020; 2020():7050146. PubMed ID: 32377272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.
    Chan JM; Oh WK; Xie W; Regan MM; Stampfer MJ; King IB; Abe M; Kantoff PW
    J Clin Oncol; 2009 Aug; 27(22):3577-83. PubMed ID: 19528373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.